Early Cognitive Impairment associated with a parkinsonian animal model: synaptic plasticity and initial approaches with IGF-1 gene therapy

HERRERA M.; OTAMENDI ANDREA; CHAMPARINI LEANDRO; CALFA G.; BELLINI MJ; MOLINA V.; HEREÑÚ CB

Cordoba

Jornada; Jornadas ?10º aniversario del Instituto de Farmacología Experimental de Córdoba (IFEC); 2018

Instituto de Farmacología Experimental de Córdoba (IFEC)? Facultad de Ciencias Químicas (UNC) ? CONICET

AbstractParkinson´s disease (PD) is a neurodegenerative disorder that results from a progressive dopaminergic neuronal loss. It is considered amultifactorial condition due to the multiplicity of symptoms experienced by patients. While this condition is known for its characteristicmotor deficits, patients also have wide variety of non-motor symptoms, such as impaired learning and memory deficits, which severelyaffect their quality of life. These non-motor symptoms result from the dysfunction of interconnected systems, including the striatum, theneocortex and the hippocampus. Growth factors are new targets for therapeutical approaches. Insulin-like growth factor-1 (IGF-1) is anendogenous peptide transported across the blood brain barrier that is protective in several brain injury models, including in an animal modelof parkinsonism.